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Abstract
Additional complexity in the post-translational modification of proteins by ubiqui-
tin is achieved by ubiquitin phosphorylation, for example within PINK1-parkin medi-
ated mitophagy. We performed a preliminary proteomic analysis to identify proteins
differentially modified by ubiquitin in HEK293T, compared to phosphomimetic ubiq-
uitin (Ser65Asp), and identified small ubiquitin-related modifier 2 (SUMO2) as a
candidate. By transfecting SUMO2 and its C-terminal–GG deletionmutant, along with
phosphomimetic ubiquitin, we confirm that ubiquitin modifies SUMO2, rather than
vice versa. Further investigations revealed that transfected SUMO2 can also be con-
jugated by endogenous phospho-Ser65-(poly)ubiquitin in HEK293T cells, pointing to a
previously unappreciated level of complexity in SUMO2 modification, and that unan-
chored (substrate-free) polyubiquitin chains may also be subject to phosphorylation.
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1 INTRODUCTION
Ubiquitin is a small (8.6 kDa) 76-residue regulatory protein which is
found ‘ubiquitously’ in the cytoplasm and nucleus of eukaryotic cells
Abbreviations: CCCP, carbonyl cyanidem-chlorophenyl hydrazine; DLB, denaturing lysis
buffer; DUB, deubiquitinase; E2, E2 ubiquitin conjugating enzyme; E3, E3 ubiquitin ligase; EV,
empty vector; GFP-SUMO2, Green fluorescent protein tagged SUMO2; HF, His FLAG-tag;
HF-SUMO2, His FLAG-tagged SUMO2; HF-UbS65D, His FLAG-tagged ubiquitin
Serine65Aspartate phosphomimetic mutant; HF-UbWT, His FLAG tagged ubiquitin wild-type;
IMAC, immobilisedmetal affinity chromatography;MuBiSiDa, mammalian ubiquitylation site
database software; NETN, Sodium EDTA Tris NP-40 buffer; PEI, polyethylenimine; pkk223-3,
pKK223-3 vector, GenBank:M77749; pSer65, phospho-Ser65; RUBI, Rapid ubiquitylation
software; S65D_UbpKK223-3, Human ubiquitin Ser65Aspmutant cloned into a pKK223-3
vector; SMART, simple modular architectural research tool; SUMO2∆GG, C-terminal –GG
deleted SUMO2 variant incapable of substrate conjugation but able to accept
post-translational modifications; Ub, ubiquitin; UbiSite, ubiquitylation site prediction
software; Ubpkk233-3, human ubiquitin wild-type cloned into a pKK223-3 vector; UbS65D,
ubiquitin Serine65Aspartate phosphomimetic mutant; UbWT, ubiquitin wild-type; ZnF-UBP,
zinc finger ubiquitin binding domain; ZnF-UBP-Sepharose, zinc finger ubiquitin binding
domain coupled to Sepharose
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and is a post-translational modifier of other proteins [1, 2]. Protein
ubiquitylation is a process inwhich ubiquitin is covalently attached to a
specific protein target in a three-step enzymatic cascade involving the
action of an E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating
enzyme and E3 ubiquitin-ligase enzyme [3]. The functional conse-
quences of ubiquitylation vary as a result of recognition by different
ubiquitin-binding modules which are able to distinguish different
(poly)ubiquitin modifications [4]. For example, monoubiquitylation has
been implicated in the endocytic trafficking of certain cargo proteins
for example, GTPases and receptors for example, epidermal growth
factor receptor, to specific cellular compartments at different stages
of the endocytic pathway. Lys48-linked polyubiquitylation that is,
polyubiquitin chains linked via Lys48 of ubiquitin, have classically
been linked to targeting substrates for proteasomal degradation [5].
In contrast, Lys63-linked polyubiquitin chains function as scaffolds to
assemble signalling complexes including activation of the transcrip-
tion factor NF-κB, involved in inflammatory and immune response.
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Ubiquitylation of ULK1 with Lys63-linked polyubiquitin by TRAF6
activity, stabilises ULK1 thereby promoting the initiation of autophagy
and autophagosome formation. In addition, ligation of Lys63-linked
polyubiquitin to BECLIN 1 by TRAF6 (E3), promotes BECLIN 1-
mediated induction of autophagy [6]. Parkin-mediated Lys63-linked
polyubiquitylation is also a signal that promotes the sequestration of
misfolded proteins into aggresomes via HDAC6-dynein motor com-
plex for subsequent autophagic clearance [7]. Activation of the NF-κB
pathway via activation of TAK1 which in turn phosphorylates and
activates IκB kinase (IKK) by unanchored (substrate-free) Lys63-linked
polyubiquitin chain assembled via UBE2N/UBE2V1 (E2) and TRAF6
enzymes has also been demonstrated [8]. Dysfunction of ubiquitin
signalling has been implicated in a wide range of diseases including
cancer [9], neurodegeneration [10], cardiovascular [11] and metabolic
disorders [12].
More recently, the demonstration that ubiquitin itself can be mod-
ified through phosphorylation by kinases including PINK1 provided
a major breakthrough linking two fundamental signalling pathways
in cells; phosphorylation and ubiquitylation [13–15]. Ubiquitin can
be phosphorylated on Ser, Thr and Tyr residues, which may further
modulate its regulatory functions; however, the full physiological and
indeed pathological significance of these additional modifications is
unclear. In addition to activation of parkin, the consequences of Ser65
phosphorylation of ubiquitin on the structure, polyubiquitin chain
assembly, recognition, hydrolysis and downstream mitochondrial
homeostasis have been reported [16, 13–15, 17, 18]. Studies have
suggested that phospho-Ser65-ubiquitin is the parkin receptor on
damaged mitochondria [19], but the pathophysiological relevance of
this post-translational modification in the PINK1-parkin mitophagy
pathway in neurons and brain tissue is not fully understood. While
phosphorylation of the modifier protein, ubiquitin, further increases
complexity, it also provides more selectivity and specificity for an
apparently universal ubiquitylation process [20, 21]. Although the
function of Lys63-linked phospho-Ser65-(poly)ubiquitin in parkin
activation and directing damaged mitochondria to the autophagy
pathway has been established, the broadermolecular consequences of
ubiquitin phosphorylation, including targets of phosphoubiquitin, have
not been fully explored [20, 14, 22, 23, 18, 24].
Further, comparatively little is known about the regulation of unan-
chored polyubiquitin chains. In the same way that conjugated polyu-
biquitin chains can be considered to represent an ‘ubiquitin code’, dis-
tinct sub-populations of unanchored polyubiquitin chains are likely
to underlie different biological activities [25]. An unanchored polyu-
biquitin chain is a free ubiquitin chain that is not conjugated to a
substrate protein. Knowledge of the range of fundamental processes
that may be regulated by unanchored polyubiquitin and unanchored
phosphorylated-polyubiquitin chains, as well as the precise molecu-
lar composition of these ubiquitin polymers (i.e., presence of differ-
ent isopeptide linkages, etc.) is also lacking. Whether, like conjugated
polyubiquitin, such substrate-free ubiquitin assemblies are also regu-
lated by modifications such as phosphorylation, is unclear, but previ-
ously established robust purification protocols mean that such ques-
tions can now be addressed [26].
Significance Statement
Eukaryotes have an extensive repertoire of PTMs such as
phosphorylation and ubiquitylation. Phosphorylation of Ser-
ine residues of ubiquitin modifies its structure, polyubiquitin
chain assembly and deubiquitylase-dependent chain hydrol-
ysis, providing an additional layer of regulation in ubiqui-
tin signal functions. Site-specific ubiquitin phosphorylation
generating pSer65-ubiquitin in the PINK1-parkin pathway is
relevant in diseases associated with mitochondrial dysfunc-
tion including Parkinson’s disease, cancer, cardiovascular and
metabolic disorders.
In the same way that conjugated polyubiquitin chains can be
considered to represent an ‘ubiquitin code’, distinct subpop-
ulations of unanchored (substrate-free) polyubiquitin chains
are likely to exert different biological activities. Knowledge
of the range of fundamental processes thatmay be regulated
by unanchored polyubiquitin as well as the precisemolecular
composition of these ubiquitin polymers is also lacking.
This project used proteomic approaches to identify and
catalogue mammalian target proteins modified by covalent
attachment of pSer65-(poly) ubiquitin from cultured human
embryonic kidney cells and identified SUMO2as a candidate,
and indicated that unanchored polyubiquitin chainsmay also
be subject to phosphorylation.
We hypothesised that there are many other protein targets beyond
mitochondrial outer membrane proteins [18] that are covalently
modified by phosphorylated ubiquitin. This investigation therefore
attempted to identify novel mammalian proteins that are modi-
fied by covalent modification with phospho-Ser65-(poly)ubiquitin in
HEK293T cells.
2 MATERIALS AND METHODS
2.1 Expression of His FLAG-tagged ubiquitin and
phosphomimetic Ser65Asp mutant
Human ubiquitin wild-type (UbWT) and Ser65Asp (UbS65D) phos-
phomimetic mutant genes were amplified by PCR from a Ubpkk223-3
construct (human ubiquitin cloned into a pKK223-3 vector, GenBank:
M77749) and S65D_Ubpkk223-3 mutant constructs to engineer a
NotI cleavage site directly upstream of the atg ubiquitin start codon
in the forward primer (CACACGCGGCCGCATGCAGATCTTCGTCAA-
GACGTTA) and an ApaI recognition site downstream of the ubiquitin
stop codon (tga) in the reverse primer (CACACGGGCCCTCAACCAC-
CTCTTAGTCTTAAGAC) (SIGMA-ALDRICH Company Ltd, Gillingham,
UK). Following gel purification, cDNAs obtained were digested
with ApaI (1 U/50 μL) at 25◦C. After 3 h of incubation, ApaI was
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heat-inactivated at 65◦Con an IncublockMicrotube Incubator (Labnet
International Inc., NJ, USA) for 20 min before NotI-HF (1 U/50 μL)
was added at 37◦C for another 3 h. cDNA digests were purified by
gel extraction and ligated into the NotI-HF/ApaI restriction sites of
the pre-cut N-terminal His FLAG-tagged pcDNA3.1Zeo+ vector (i.e.,
pcDNA3.1Zeo+, addgene Catalog Number V86020, into which a
His6-FLAG oligo was ligated to generate the His-FLAG tag) following
post-restriction alkaline phosphatase treatment, to allow expression
in mammalian cells. Construct DNAs were amplified by transforming
into competent Escherichia coli XL10-Gold strains and extracted by the
QIAprep Spin Maxiprep protocol. Sequences were confirmed by DNA
sequencing using CMV promoter 5’/Bovine growth hormone poly (A)
3’ primer pair.
Cultured HEK293T cells at ∼80% confluence were transiently
transfected with the purified His FLAG-tagged pcDNA3.1Zeo+ empty
vector, UbWT or UbS65D mutant construct (HF-EV, HF-UbWT, HF-
UbS65D) by the polyethylenimine (PEI) transfection protocol [27, 28].
10 μg of eachDNAwas diluted in 250 μL of PBSwhile 30 μL of 1mg/mL
PEI solution was diluted in 250 μL of PBS per 10 cm dish. The PEI/DNA
complex was prepared by adding PEI dropwise to each DNA solution,
mixing gently and allowing to sit at room temperature for 15 –30 min.
Each complex was then added dropwise to the appropriate dish of
cells in media containing 2% FBS (DMEM high glucose, 2% FBS, 1%
Penicillin-Streptomycin). Cellswere returned to the tissue culture incu-
bator at 5%CO2, 100%humidity for 18 h after whichmedia containing
2% FBS was replaced with complete media (DMEM high glucose, 10%
FBS, 1% Penicillin-Streptomycin) and further incubated for 48 h in the
tissue culture incubator.
2.2 IMAC purification of ubiquitin-modified
proteins
Cells fromeach transfectionwere scraped in 6mLpre-chilled PBS after
which 10% of each cell suspension was pelleted at 3000 × g for 5 min
at 4◦C. After discarding the PBS by carefully pipetting, each pellet was
re-suspended in 50 μL of 1 × Laemmli sample loading buffer (60 mM
Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01%
bromophenol blue) containing 200 mM imidazole in order to subse-
quently elute His-tagged protein from the Ni2+ resin. The remaining
90% of cell suspensions were in turn pelleted at 3000 g for 5 min
and re-suspended in 4 mL Denaturing Lysis Buffer, pH 8.0 (DLB; 6 M
Guanidine.HCl (GnHCl), 20mMNa2HPO4/NaH2PO4, pH 8.0, 500mM
NaCl, 20 mM imidazole). Proteins that had covalently attached to HF-
UbWT or HF-S65D mutant proteins in cell sample lysate were puri-
fied by small-scale denaturing IMAC. Briefly, 30 μL of His-Select Nickel
Affinity Gel resin for purification of His-tagged proteins per 10 mL
QIAGEN disposable affinity column were prepared by washing each
resin 1 × 15 min with 10 mL of DLB rotating gently at room tem-
perature after which DLB was allowed to flow through columns by
gravity. To shear released genomic DNA and make the extracted solu-
tion less viscous to pipette, cells were sonicated 3 × 30 s on ice and
rotated gently on an end–over-end rotator mixer for 10 min at 4◦C to
ensure complete cell lysis. Cell fragments were pelleted at 13,000 rpm
in a benchtop centrifuge for 10 min. Supernatants containing protein
extracts were transferred to previously prepared IMAC resin in affin-
ity chromatography columns and rotated gently for 4 h at room tem-
perature. Following protein binding, the supernatant was allowed to
flow through by gravity after which beads were successively washed
1 × 15 min with 10 mL of wash buffer-1 (WB1; 8 M Urea, 20 mM
Na2HPO4/NaH2PO4, pH 8.0, 500 mM NaCl, 20 mM imidazole), 2
(WB2; 8 M Urea, 20 mM Na2HPO4/NaH2PO4, pH 6.0, 500 mM NaCl,
20 mM imidazole), 3 (WB3; WB2 + 0.2% v/v Triton X-100), 4 (WB4;
WB3+ 0.1% v/v Triton X-100) and lastly with PBS. 25 μL of beads with
associated proteins were dried at 2000 g for 1min and stored at -20◦C
for LC-MS/MS identification of bound proteins. Proteins on remaining
5 μL of beadswere elutedwith Laemmli sample loading buffer contain-
ing 200 mM imidazole. SDS-PAGE was performed on eluted samples
and analysed by immunoblotting resolved proteins with anti-His-tag
(AbD Serotec, Kidlington, UK) or anti-(VU-1) ubiquitin (Life Sensors,
PA, USA) antibodies and visualised by ECL. Following ECL, blots were
stripped and reprobedwith anti-ß-actin antibodies (SIGMA-ALDRICH,
Gillingham, UK).
2.3 Identification of proteins modified by
covalent attachment of phosphoubiquitin by
LC-MS/MS
The shotgun proteomic approach was employed to identify proteins in
IMAC-purified mixtures as detailed in literature [29–31]. Protein on
∼25 μL of beadswere initially reduced by addition of 50mMDTT, alky-
lated by treatment with 100 mM chloroacetamide and subjected to
tryptic digestionusing0.02mg/mLsequencing-grade trypsin. Resulting
peptidemixtures obtained, were separated by tandemmass spectrom-
etry (MS/MS) on an LTQ-Orbitrap-Velos spectrometer (Thermo Scien-
tific, Wilmington, USA) with nano-flow liquid chromatography (Dionex
Ltd, Camberley, UK). Proteome Discoverer (version 1.4.0.288, Thermo
Scientific, Wilmington, USA) was used to process the raw data file
obtained from the LC-MS/MS acquisition. The file was then searched
usingMascot (version 2.2.04,Matrix Science Ltd,Marylebone, London,
UK) against the UniProt Human_2018_03 database. Peptides were
identified in data-dependent mode combining Mascot and X! Tandem
search engines to validate MS/MS assigned spectra from Proteome
Discoverer. The peptide andMS/MS tolerance were set to 10 ppm and
0.02Da, respectively. Fixedmodificationswere set as alkylation of cys-
teine, andvariablemodifications set asdeamidationofAsnandGln, and
oxidation of Met and Pro residues. Peptides were identified at greater
than 95.0% probability, with a minimum of two peptides required for
protein identification. IMAC and LC-MS/MS was performed on an ini-
tial small-scale pilot screen, and a subsequentmore preparative scaled-
up repeat, with proteins of interest found to be overlapping in the anal-
yses triaged for biochemical confirmation. In each case, LC-MS/MSwas
conducted in six replicates.
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2.4 Confirmation of the covalent modification of
transfected SUMO2 by ubiquitin in vivo
SUMO2 and SUMO2∆GG (a C-terminal—GG deleted SUMO2 vari-
ant incapable of substrate conjugation but able to accept post-
translational modifications) cDNAs engineered in pEGFP-C1 vector to
generate GFP-tagged SUMO2-GG and GFP-tagged SUMO2∆GG con-
structs were co-transfected with equal amounts of HF-UbWT con-
struct created earlier into HEK293T cells as follows; GFP-SUMO2-GG
and HF-UbWT, and GFP-SUMO2∆GG and HF-UbWT. Following har-
vesting, cells were lysed in DLB and proteins were purified by IMAC as
describedpreviously. Afterwashes, 25μLof 1× Laemmli loading buffer
containing 200 mM imidazole was added to elute bound proteins.
Eluted proteins were separated by SDS-PAGE and analysed by west-
ern blottingwith anti-(VU-1) ubiquitin and rabbit anti-GFP (Abcam plc.,
Cambridge, UK) (1:2000) antibodies.
2.5 Modification of transfected SUMO2 by
endogenous phospho-Ser65-ubiquitin
HEK293T cells seeded at 1.5 × 106 cells per 10 cm dish were trans-
fected at ∼80% confluence with SUMO2 cloned into pcDNA3.1Zeo+
to express a His-FLAG-tagged SUMO2 (HF-SUMO2) by the PEI pro-
tocol outlined above. 40 h after incubation in fresh complete culture
media, themediawas replacedwith complete culturemedia containing
10 μM CCCP, an inhibitor of oxidative phosphorylation and returned
to the tissue culture incubator (5% CO2, 100% humidity) for 8 h prior
to harvesting in PBS. CCCP is known to increase total or conjugated
phospho-Ser65-(poly)ubiquitin and has been used to demonstrate the
subsequent recovery of cells from oxidative stress and in mitophagy
[16, 13]. The cells were then lysed in DLB and proteins bound to HF-
SUMO2 were purified by IMAC as previously described. Bound pro-
teins were eluted in 1 × Laemmli loading buffer containing 200 mM
imidazole, resolved by SDS-PAGE and immunoblotted with anti-(VU-
1) ubiquitin and phospho-Ser65-ubiquitin (Merck KGaA, Darmstadt,
Germany) antibodies. Following western blot analysis, the ubiquitin
blot was stripped and reprobed with anti-His-tag antibody while the
phospho-Ser65-ubiquitin blot was reprobed with monoclonal anti-
FLAGM2 antibody (Millipore, Watford, UK) (1:2500). Throughout this
experiment Empty His-tagged vector (HF-EV) was added as an expres-
sion and SUMO2modification control.
2.6 Detection of Ser65 phosphorylation in
purified unanchored (poly)ubiquitin chains in
HEK293T cells
CulturedHEK293T cells at∼80% confluencewere treatedwith 10 μM
CCCP by replacing completemedia with freshmedia containing 10 μM
CCCP in DMSO or diluent DMSO only and placed in a tissue cul-
ture incubator at 5% CO2, 100% humidity for 8 h. Cell debris was
pelleted following cell lysis and sonication at 3 × 30 s on ice. The
ZnF-UBP domain affinity chromatography protocol [26] was used
to purify unanchored (poly)ubiquitin from 6.0 mg protein of CCCP-
treated HEK293T cells in NETN buffer (200 mM Tris, 100 mM NaCl,
1 mM EDTA, 0.1% NP-40, pH 8.0) containing phosphatase inhibitor
cocktail (1:1000) and mammalian protease inhibitors (1:1000). Pro-
tein quantitation was achieved by BCA assay using the Pierce BCA
Protein Assay Kit (ThermoFisher Scientific, Waltham, USA). Subse-
quently, 50 μL of ZnF-UBP-Sepharose bait captures were eluted into
50 μL of sample loading buffer. Eluted unanchored polyubiquitin chains
obtained were resolved on 5–20% SDS-PAGE gradient gels, trans-
ferred onto nitrocellulose membrane and western blotted. After prob-
ing with both rabbit anti-phospho-Ser65-ubiquitin primary (1:1000)
and rabbit polyclonal secondary (Dako Denmark, Glostrup, Denmark,
1:2000) antibodies, the blot was visualised on X-ray film after ECL
treatment.
3 RESULTS AND DISCUSSION
3.1 IMAC-purification of ubiquitin-modified
proteins from HEK293T cells
We performed a pilot screen of cellular targets of (phospho-
mimetic)ubiquitin by initially transfecting HEK293T cells with
HF-UbWT or phosphomimetic HF-UbS65D constructs, and purified
covalently modified endogenous proteins by denaturing IMAC. Ubiq-
uitin immunoreactivity, a combination of endogenous and transfected,
was detected in all input samples as expected (Figure 1) with high
molecular weight smears indicating incorporation of transfected
ubiquitin (anti-His) into protein conjugates. As an indication of suc-
cessful IMAC purification, no ubiquitin immunoreactive smears were
observed in the IMAC-purified eluates of HF-EV (empty vector) con-
trol. Anti-His blotting of inputs and purified samples from HF-UbWT
and HF-UbS65D transfections revealed (transfected ubiquitin) reac-
tivity with apparently higher abundance for the phosphomimetic, with
anti-β-actin immunoblotting confirming approximately equal loads in
the input samples. Overall, this is suggestive of increased conjugation
of endogenous proteins with HF-UbS65D compared to HF-UbWT in
HEK293T cells, and/or that the phosphomimetic is more resistant to
deubiquitylation, consistent with previous observations in yeast cells
[23, 18].
3.2 Identification of ubiquitin-modified proteins
from HEK293T cells by mass spectrometry
Denaturing IMAC-purified samples were subjected to LC-MS/MS
analysis in order to catalogue endogenous proteins modified by trans-
fected ubiquitin. The initial analysis identified a total of 32 proteins
in purified fractions from transfections with HF-UbWT, HF-UbS65D,
or both (but not HF-EV controls), from a minimum of two peptide
sequences, including 19 associated with HF-UbS65D only (Table
S1). Data presented on Table 1 represent data from which controls
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F IGURE 1 Immunoblot of purified protein targets of ubiquitylation by recombinant wild-type and Ser65Asp-ubiquitin in HEK293T cells. His
FLAG-taggedUbWT andUbS65Dmutant proteins were expressed in HEK293T cells. Following cell lysis in DLB buffer and sonication at 3 x 30 s on
ice, cell fragments were pelleted at 13,000 g for 10min. Proteins bound to UbWT andUbS65Dwere purified by IMAC, resolved by SDS-PAGE and
immunoblotted against VU-1 ubiquitin (left panel) or anti-His-tag antibodies (right panel). Blots were stripped and reprobedwith anti-β-actin
antibodies (lower panels)
(proteins identified in transfects with HF-EV controls) had been
manually excluded. One of these HF-UbS65D-modified proteins was
SUMO2 (Figure 2). A subsequent more preparative scaled-up repeat
using four times the amount (by protein) of transfected cell lysates
following the same protocol described above, identified a total of
316 different proteins in corresponding IMAC-purified samples were
detected, again including SUMO2 (Table S1) in the HF-UbWT purifi-
cations, but with increased ‘total spectrum counts’ (semi-quantitative
indicator of protein abundance in Scaffold) in the HF-UbS65D purifi-
cation. Although different scales do not permit detailed comparison of
the proteomic screens, together eight overlapping proteins; ALDOA,
CD9, CD47, ESYT1, HNRNPC, HSPA8, SLC6A15 and SUMO2 were
identified in both experiments (∼25% of proteins in the small-scale
purification found to be modified in the more preparative analysis
regardless of whether they were modified by UbWT or UbS65D
(Table 1 and Table S1). Across both experiments, a total of 22 out of
93 residues of the endogenous SUMO2 sequence were detected in
the purified samples from HF-UbS65D-transfected cells, represent-
ing sequence coverage of 24% (Figure 2). These analyses therefore
suggested (preferential) modification of SUMO2 by transfected phos-
phomimetic HF-UbS65D compared to HF-UbWT in HEK293T cells.
3.3 Validation of SUMO2 as a target of ubiquitin
in HEK293T cells
SUMO2 has not previously been described as target of phospho-
Ser65-ubiquitin, although mixed/hybrid chains with ubiquitin have
been reported [32, 33], and ubiquitylation prediction software pro-
grammes (i.e., UbiSite, RUBI and MuBiSiDa) analyses conducted in
this project indicate the presence of ubiquitylation sites. SUMO2 was
therefore considered a potentially novel covalent target of phospho-
Ser65-ubiquitin in HEK293T cells. As SUMO2 itself is an ubiquitin-like
modifier, we first determined whether it was indeed undergoing
modification with ubiquitin, or itself was the modifier of ubiquitin, in
subsequent experiments. To this end, we co-transfected HEK293T
cells with HF-UbWT and GFP-SUMO2 with or without its critical C-
terminal diglycine residues that are required tomediate conjugation to
targets,whilst not affecting the ability to ‘accept’ conjugation (i.e., GFP-
SUMO2∆GG). After denaturing IMAC-purifications, anti-ubiquitin
immunoblotting indicated that deletion of the diglycine residues of
transfected SUMO2 had no effect on its ability to be modified by
HF-UbWT, with high molecular weight ubiquitin conjugates present
in purified fractions (Figure 3). GFP-tagged protein reactive bands
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TABLE 1 LC-MS/MS analyses of HEK293T proteins captured on denaturing IMAC after expression of HF-EV control, UbWT andUbS65D
Experiment 1
No GN Identified proteins
Accession
number Mwt (kDa) HF-EV UbWT UbS65D
1 ALDOA Fructose-bisphosphate aldolase A (Fragment) OS=
Homo sapiens PE= 1 SV= 1
H3BMQ8 (+6) 15 0 2 0
2 CASP14 Caspase-14OS=Homo sapiens PE= 1 SV= 2 P31944 28 0 4 0
3 CD47 Leukocyte surface antigen CD47OS=Homo sapiens
PE= 1 SV= 1
Q08722 35 0 0 2
4 CD9 Tetraspanin OS=Homo sapiens PE= 1 SV= 1 A6NNI4 (+2) 18 0 0 2
5 DCD Dermcidin OS=Homo sapiens PE= 1 SV= 2 P81605 11 0 2 0
6 DERL1 Derlin OS=Homo sapiens PE= 1 SV= 1 B4E1G1 (+1) 17 0 0 2
7 DSG1 Desmoglein-1OS=Homo sapiens PE= 1 SV= 2 Q02413 114 0 0 4
8 EIF3CL Eukaryotic translation initiation factor 3 subunit
C-like protein OS=Homo sapiens PE= 3 SV= 1
B5ME19 (+1) 105 0 0 2
9 ESYT1 Extended synaptotagmin-1OS=Homo sapiens PE=
1 SV= 1
Q9BSJ8 123 0 0 3
10 FAF2 FAS-associated factor 2OS=Homo sapiens PE= 1
SV= 2
Q96CS3 53 0 2 2
11 FLG Filaggrin OS=Homo sapiens PE= 1 SV= 3 P20930 435 0 0 2
12 FNDC3A Fibronectin type III domain containing 3A, isoform
CRA_f OS=Homo sapiens PE= 1 SV= 1
G5E9× 3 (+1) 75 0 0 2
13 HIST2H3PS2 HistoneH3OS=Homo sapiens PE= 1 SV= 1 Q5TEC6 15 0 4 0
14 HNRNPC Heterogeneous nuclear ribonucleoproteins C1/C2
OS=Homo sapiens PE= 1 SV= 1
B2R5W2 (+6) 32 0 3 0
15 HSPA8 Heat shock cognate 71 kDa protein OS=Homo
sapiens PE= 1 SV= 1
E9PKE3 (+2) 69 0 0 3
16 JUP Junction plakoglobinOS=Homo sapiens PE= 1 SV=
3
P14923 82 0 0 9
17 KDELR1 ER lumen protein-retaining receptor 1OS=Homo
sapiens PE= 1 SV= 1
P24390 25 0 0 3
18 PARP1 Poly [ADP-ribose] polymerase 1OS=Homo sapiens
PE= 1 SV= 4
P09874 113 0 2 0
19 POC1B Polypeptide N-acetyl galactosaminyl transferase
OS=Homo sapiens -GALNT4 PE= 3 SV= 1
F8VUJ3 (+1) 66 0 2 0
20 PTK7 Inactive tyrosine-protein kinase 7OS=Homo
sapiens PE= 1 SV= 2
Q13308 118 0 0 2
21 S100A8 Protein S100-A8OS=Homo sapiens PE= 1 SV= 1 P05109 11 0 3 0
22 S100A9 Protein S100-A9OS=Homo sapiens PE= 1 SV= 1 P06702 13 0 2 0
23 SBSN Suprabasin OS=Homo sapiens PE= 1 SV= 2 Q6UWP8 61 0 0 2
24 SLC39A7 Zinc transporter SLC39A7OS=Homo sapiens PE=
1 SV= 2
Q92504 50 0 3 0
25 SLC6A15 Sodium-dependent neutral amino acid transporter
B(0)AT2OS=Homo sapiens PE= 1 SV= 1
Q9H2J7 82 0 0 2
26 SRRM2 Serine/arginine repetitivematrix protein 2OS=
Homo sapiens PE= 1 SV= 2
Q9UQ35 300 0 2 0
27 STX4 Syntaxin-4OS=Homo sapiens PE= 1 SV= 2 Q12846 34 0 0 2
28 SUMO2 Small ubiquitin-relatedmodifier 2OS=Homo
sapiens PE= 1 SV= 3
P61956 11 0 0 3
29 TMEM38B Transmembrane protein 38B, isoformCRA_bOS=
Homo sapiens PE= 1 SV= 1
A0A0A0MRS4
(+1)





No GN Identified proteins
Accession
number Mwt (kDa) HF-EV UbWT UbS65D
30 TMEM65 Transmembrane protein 65OS=Homo sapiens PE=
1 SV= 2
Q6PI78 25 0 2 0
31 TTYH3 Protein tweety homolog 3OS=Homo sapiens PE= 1
SV= 3
Q9C0H2 58 0 0 2
32 YIF1A Protein YIF1AOS=Homo sapiens PE= 1 SV= 1 A6NGW1 (+1) 26 0 0 2
Numerical values in final three columns indicate total spectrum counts.
Minimum# peptides= 2, Number of replicates= 6.
Abbreviations: HF-EV, His FLAG-tagged empty vector; IMAC, immobilised metal affinity chromatography; UbWT, ubiquitin wild-type; UbS65D, Ser65Asp-
ubiquitin; SUMO2, small ubiquitin-relatedmodifier 2
F IGURE 2 LC-MS/MS analyses of endogenous SUMO2 captured by denaturing IMAC after expression of His FLAG-tagged
Ser65Asp-ubiquitin (HF-UbS65D) in HEK293T cells. Across two experiments, a total of 22 out of 93 residues of the endogenous SUMO2 primary
sequence (highlighted) were detected, representing sequence coverage of 24%
F IGURE 3 Validation of the covalent modification of proteins by phospho-Ser65-ubiquitin in HEK293T cells. His FLAG-taggedwild-type
ubiquitin (HF-UbWT) was co-transfected with GFP-tagged SUMO2 or GFP-tagged SUMO2∆GG (a C-terminal –GG deleted SUMO2 variant
incapable of substrate conjugation but able to accept post-translational modifications) in HEK293T cells. Cells were lysed in DLB and sonicated 3x
30 s on ice. Cell protein extracts were purified by the IMAC protocol. Proteins bound to resin were eluted with 1x Laemmli loading buffer
containing 200mM imidazole after washes and further resolved by SDS-PAGE prior to western blot analysis against anti-(VU-1) ubiquitin and
anti-GFP antibodies. GFP-tagged protein reactive bands were observed at the expected weight of∼48.4 kDawhich suggests that IMAC-purified
proteins retained GFP reactivity in the absence of C-terminal diglycine residues of SUMO2 (SUMO2∆GG) indicative of modification of SUMO2
sequences by ubiquitin in HEK293T cells
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F IGURE 4 Biochemical validation of SUMO2 as covalent target of endogenous phospho-Ser65-ubiquitin. His FLAG-tagged SUMO2was
overexpressed in HEK293T cells. Forty hours after transfection, cells were treated with 10 μMCCCPwhich is known to increase total or
conjugated phospho-Ser65-(poly)ubiquitin, for extra 8 h prior to harvesting in PBS. Cells were lysed in DLB and proteins bound to His
FLAG-tagged SUMO2were purified by IMAC. Proteins were eluted from the resin with 1X Laemmli loading buffer containing 200mM imidazole
following washes. Eluted proteins were then resolved by SDS-PAGE and immunoblotted with anti-(VU-1) ubiquitin and anti-pSer65-ubiquitin
antibodies. After ECL, blots were stripped and respectively reprobedwith anti-His-tag and anti-FLAG-tag antibodies
were observed at the expected weight of ∼48 kDa which suggests
that IMAC-purified proteins retained GFP reactivity in the absence
of SUMO2 C-terminal diglycine residues (SUMO2∆GG) indicative of
modification of SUMO2 sequences by ubiquitin. These observations
suggest that ubiquitin covalently modified SUMO2 (Figure 3, right
panel) with SUMO2 representing the ‘proximal’ moiety in the ‘hybrid’
chain in HEK293T cell line.
3.4 Confirmation of SUMO2 as a covalent target
of endogenous phospho-Ser65-ubiquitin
In order to induce the formation of endogenous phospho-Ser65-
ubiquitin since steady-state levels in cells are relatively low [34],
HEK293T cells transfected with His FLAG-tagged SUMO2 (HF-
SUMO2) or empty vector (HF-EV) control were treated with 10 μM
CCCP (an inhibitor of oxidative phosphorylation which is also known
to increase phosphorylation of endogenous phospho-Ser65-ubiquitin)
for 8 h after which proteins covalently linked to HF-SUMO2 were
purified by denaturing IMAC and analysed by western blotting (Fig-
ure 4). Ubiquitin-reactive smearswere observed in eluates from IMAC-
purified samples only when HF-SUMO2 was transfected, again with
SUMO2 modification with endogenous ubiquitin evident (Figure 4,
left panel). Accordingly, IMAC-purified samples were also positive for
FLAG reactivity only when HF-SUMO2 was transfected. The anti-
phospho-Ser65-ubiquitin blot of purified samples revealed distinct
reactive bands indicative of the presence of endogenous phospho-
Ser65-(poly)ubiquitin which had been purified by denaturing IMAC
along with HF-SUMO2. Phospho-Ser65-(poly)ubiquitin immunoreac-
tive bands were absent in controls (Figure 4, right panel). The pat-
tern of phospho-Ser65-(poly)ubiquitin observed also corresponded to
that on the anti-FLAG reactive smear, indicating covalent interaction of
phosphoubiquitin with HF-SUMO2. The biochemical detection of the
interaction between endogenous phospho-Ser65-(poly)ubiquitin and
SUMO2 is illustrated by annotation in Figure 4 (extreme right).
Classically, protein SUMOylation is predominantly confined to the
nucleus and unlike ubiquitylation, SUMOylated proteins are not tar-
geted for degradation. SUMOylation of target proteins have several
functions such as protein stability, nuclear-cytosolic transport, tran-
scriptional regulation, cell cycle regulation in invertebrates and sig-
nal transduction. Results obtained therefore suggests that modifi-
cation of SUMO2 with phospho-Ser65-ubiquitin might have several
consequences in SUMO2 function by altering signals for SUMO2
degradation, DUB-mediated deubiquitylation or induction of unknown
phospho-ubiquitin-SUMO2 hybrid chain effects in HEK293T cells.
Nevertheless, replicating these experiments in different cell lines
using HEK293T as vehicle will enable conclusive evidence to be
drawn.
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F IGURE 5 Detection of Ser65 phosphorylation in endogenous unanchored (poly)ubiquitin in HEK293T cells. 6.0 mg of HEK293T protein
lysate in NETN buffer previously treated for 8 hwith 10 μMCCCP (+CCCP) or diluent DMSO (-CCCP) were purified by ZnF-UBP domain affinity
chromatography using 100 μL of 10mg/mL ZnF-UBP protein on beads. Captured proteins were resolved by SDS-PAGE and immunoblotted with
VU-1 ubiquitin or phospho-Ser65-ubiquitin antibodies. Commercial phospho-Ser65-ubiquitin was used as a positive control of Ser65
phosphorylation of unanchored (poly)ubiquitin chains. Traces of weak phospho-Ser65-ubiquitin reactivity is evident in purified fractions of
unanchored polyubiquitin, consistent with the presence of endogenous phospho-Ser65-ubiquitin
3.5 Detection of phospho-Ser65-ubiquitin in
affinity purified unanchored (poly)ubiquitin following
CCCP treatment of HEK293T cells
Unanchored polyubiquitin chains are free ubiquitin chains that are
not conjugated to a substrate protein. Given our observations that
‘hybrid’ chains consisting of phospho-Ser65-ubiquitin and SUMO2
may be physiologically relevant, we finally investigated if unanchored
polyubiquitin chains, that is, covalent assemblies of multiple ubiq-
uitins in a substrate-free form that regulate a range of different
biological pathways, also represent overlooked substrates of modi-
fication by phosphorylation [35–39, 6, 40]. Such chains (as well as
monoubiquitin) can be affinity purified using an ubiquitin-binding
domain (UBD) with high affinity exclusively for the free C-terminus
of ubiquitin (but not SUMO2), the ZnF-UBP domain denoted as
FUBE: that is, free ubiquitin-binding entity [25]. Heating of cell lysates
prior to purification is a critical step in order to resolve unanchored
polyubiquitin chains from heat-sensitive ubiquitin-protein conjugates
(Figure 5, right panel) [41]. Unanchored polyubiquitin chains were
successfully purified by ZnF-UBP-Sepharose affinity chromatography
[26] both from cells with (+CCCP) and without CCCP (+DMSO)
treatment, and not with control ZnF-UBP-Sepharose (no protein)
(Figure 5). To investigate whether unanchored polyubiquitin chains
(like substrate/SUMO2 conjugated forms) can be modified by phos-
phorylation, captured endogenous unanchored (poly)ubiquitin chains
from +CCCP-treated HEK293T cells were resolved and immunoblot-
ted with anti-phospho-Ser65-ubiquitin and VU-1 (ubiquitin) antibod-
ies. At the 8 h +CCCP time point there was evidence of weak
phospho-ubiquitin reactivity in the purified unanchored polyubiqui-
tin fraction of treated HEK293T cells consistent with low-level Ser65




His FLAG-tagged human recombinant UbWT and UbS65D mutant
were created and employed to purify protein targetsmodified by cova-
lent attachment of (poly)ubiquitin or phospho-Ser65-(poly)ubiquitin in
HEK293T cells by the denaturing IMAC protocol. Proteomic analy-
sis suggested differential modification of various potentially novel tar-
get proteins by ubiquitin compared to UbS65D including endogenous
SUMO2, with S65D phosphomimetic mutant modifying proteins more
efficiently. By transfecting GFP-SUMO2 and its C-terminal–GG dele-
tion mutant, along with ubiquitin, we confirm that ubiquitin modifies
SUMO2 rather than vice versa. Further, we found that transfected
HF-SUMO2 is modified by endogenous phospho-Ser65-ubiquitin in
HEK293T cells. SUMO2 therefore represents a novel target of Ser65-
phosphorylated ubiquitin in HEK293T cells. Endogenous unanchored
(substrate-free) polyubiquitin chains from HEK293T cells were suc-
cessfully purified by ZnF-UBP domain affinity chromatography. Addi-
tionally, we established that unanchored polyubiquitin chains may be
regulated by phosphorylation on Ser65 and illustrated that CCCP
treatment augments phosphorylation of unanchored polyubiquitin in
HEK293T cells. Further studies will investigate the biological impor-
tance of (i) ubiquitin modification of SUMO2, (ii) phospho-ubiquitin
modification of SUMO2, (iii) the role of phospho-ubiquitin in unan-
chored polyubiquitin chains in HEK293T cells.
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